Browse FOLH1

Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type II membrane protein ; SUBCELLULAR LOCATION: Isoform PSMA': Cytoplasm
Domain PF02225 PA domain
PF04389 Peptidase family M28
PF04253 Transferrin receptor-like dimerisation domain
Function

Has both folate hydrolase and N-acetylated-alpha-linked-acidic dipeptidase (NAALADase) activity. Has a preference for tri-alpha-glutamate peptides. In the intestine, required for the uptake of folate. In the brain, modulates excitatory neurotransmission through the hydrolysis of the neuropeptide, N-aceylaspartylglutamate (NAAG), thereby releasing glutamate. Involved in prostate tumor progression.; FUNCTION: Also exhibits a dipeptidyl-peptidase IV type activity. In vitro, cleaves Gly-Pro-AMC.

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006575 cellular modified amino acid metabolic process
GO:0006732 coenzyme metabolic process
GO:0006760 folic acid-containing compound metabolic process
GO:0008652 cellular amino acid biosynthetic process
GO:0016053 organic acid biosynthetic process
GO:0018200 peptidyl-glutamic acid modification
GO:0018410 C-terminal protein amino acid modification
GO:0035608 protein deglutamylation
GO:0035609 C-terminal protein deglutamylation
GO:0042558 pteridine-containing compound metabolic process
GO:0043687 post-translational protein modification
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0051186 cofactor metabolic process
Molecular Function GO:0004180 carboxypeptidase activity
GO:0004181 metallocarboxypeptidase activity
GO:0008235 metalloexopeptidase activity
GO:0008237 metallopeptidase activity
GO:0008238 exopeptidase activity
GO:0016805 dipeptidase activity
GO:0033218 amide binding
GO:0042277 peptide binding
GO:1900750 oligopeptide binding
GO:1904492 Ac-Asp-Glu binding
GO:1904493 tetrahydrofolyl-poly(glutamate) polymer binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04977 Vitamin digestion and absorption
hsa00250 Alanine, aspartate and glutamate metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-70614: Amino acid synthesis and interconversion (transamination)
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FOLH1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between FOLH1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
18272481Prostate carcinomaPromote immunityNPs were formulated by the self-assembly of an amphiphilic triblock copolymer composed of end-to-end linkage of poly(lactic-co-glycolic-acid) (PLGA), polyethyleneglycol (PEG), and the A10 aptamer (Apt), which binds to the prostate-specific membrane antigen (PSMA) on the surface of prostate cancer (PCa) cells, enabling, respectively, controlled drug release, "stealth" properties for immune evasion, and cell-specific targeting.
27406985Prostate carcinomaPromote immunity (T cell function)In vitro cross-linking of T cells with PSMA-expressing tumor cells by MOR209/ES414 triggered potent target-dependent tumor lysis and induction of target-dependent T-cell activation and proliferation.
29229829Prostate CarcinomaPromote immunityProstate tumors invariably overexpress prostate surface membrane antigen (PSMA). PPD selectively delivered polyIC into PSMA-overexpressing PC cells, inducing apoptosis, cytokine secretion, and the recruitment of human peripheral blood mononuclear cells (PBMCs).
16243819Metastatic Prostate CarcinomaPromote immunityProstate-specific membrane antigen (PSMA) is a transmembrane glycoprotein primarily expressed on benign and malignant prostatic epithelial cells. J591 is an IgG1 monoclonal antibody that targets the external domain of the PSMA.
21829171colon carcinomaPromote immunityTumor inhibition was dependent on homing to PSMA-expressing tumor cells and 4-1BB costimulation. Aptamer targeted costimulation is a broadly applicable and clinically feasible approach to enhance the costimulatory environment of disseminated tumor lesions
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FOLH1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FOLH1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1040.852
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4960.633
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5410.533
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.490.398
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7020.646
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2140.9
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8480.151
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1590.865
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.5470.133
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1570.441
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.0090.342
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0050.975
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FOLH1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.118.8-7.71
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FOLH1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FOLH1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FOLH1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FOLH1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FOLH1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FOLH1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFOLH1
Namefolate hydrolase (prostate-specific membrane antigen) 1
Aliases PSMA; NAALAD1; GCPII; glutamate carboxylase II; glutamate carboxypeptidase II; FOLH; FGCP; mGCP; N-acetylate ......
Chromosomal Location11p11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FOLH1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting FOLH1.
ID Name Drug Type Targets #Targets
DB00089Capromab pendetideBiotechFOLH11
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69
DB06928(2S)-2-{[HYDROXY(4-IODOBENZYL)PHOSPHORYL]METHYL}PENTANEDIOIC ACIDSmall MoleculeFOLH11
DB07754N-({(1R)-1-carboxy-2-[(4-fluorobenzyl)sulfanyl]ethyl}carbamoyl)-L-glutamic acidSmall MoleculeFOLH11
DB08835Spaglumic AcidSmall MoleculeFOLH11